Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to-severe COPD.

Nishtha Khatri,Sundeep Salvi,ManishK Jain,Srikanth Krishnamurthy,Akash Balki,Rahul Kodgule,Monika Tandon,Sagar Bhagat,Sagar Panchal,Wen Wu,Amol Pendse,Saiprasad Patil,Hanmant Barkate

Lung India : official organ of Indian Chest Society（2022）

引用 0|浏览2

暂无评分

摘要

FDC of GB/FF (12.5/12 μg twice daily) as a DPI provides superior bronchodilation and lung function improvement over GLY (50 μg once daily) monotherapy. It is safe and well tolerated in symptomatic COPD patients.

查看译文

关键词

COPD,India,LAMA/LABA,fixed-dose combination,formoterol fumarate,glycopyrronium

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要